[go: up one dir, main page]

WO2013128379A3 - Crystalline polymorphic forms of linagliptin - Google Patents

Crystalline polymorphic forms of linagliptin Download PDF

Info

Publication number
WO2013128379A3
WO2013128379A3 PCT/IB2013/051556 IB2013051556W WO2013128379A3 WO 2013128379 A3 WO2013128379 A3 WO 2013128379A3 IB 2013051556 W IB2013051556 W IB 2013051556W WO 2013128379 A3 WO2013128379 A3 WO 2013128379A3
Authority
WO
WIPO (PCT)
Prior art keywords
linagliptin
polymorphic forms
crystalline polymorphic
polymorphs
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/051556
Other languages
French (fr)
Other versions
WO2013128379A2 (en
Inventor
Srividya Ramakrishnan
Subbareddy Peddireddy
Lalita Kanwar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of WO2013128379A2 publication Critical patent/WO2013128379A2/en
Publication of WO2013128379A3 publication Critical patent/WO2013128379A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present application relates to crystalline polymorphs of linagliptin and to methods for their preparation. Further the present application relates to the use of the linagliptin novel polymorphs for the preparation of a medicament, and pharmaceutical compositions comprising an effective amount of the crystalline linagliptin polymorphs.
PCT/IB2013/051556 2012-02-27 2013-02-27 Crystalline polymorphic forms of linagliptin Ceased WO2013128379A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN723CH2012 2012-02-27
IN723/CHE/2012 2012-02-27
IN3401CH2012 2012-08-17
IN3401/CHE/2012 2012-08-17
IN5356CH2012 2012-12-21
IN5356/CHE/2012 2012-12-21

Publications (2)

Publication Number Publication Date
WO2013128379A2 WO2013128379A2 (en) 2013-09-06
WO2013128379A3 true WO2013128379A3 (en) 2013-10-31

Family

ID=49083398

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/051556 Ceased WO2013128379A2 (en) 2012-02-27 2013-02-27 Crystalline polymorphic forms of linagliptin

Country Status (1)

Country Link
WO (1) WO2013128379A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102442536B1 (en) 2015-09-17 2022-09-13 한미정밀화학주식회사 Linagliptin crystalline form and preparation method thereof
CN109748919A (en) * 2017-11-07 2019-05-14 四川科伦药物研究院有限公司 A kind of crystal form of Li Gelieting and preparation method thereof
TR201720515A2 (en) 2017-12-15 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A SOLID ORAL DOSAGE FORM CONTAINING LINAGLIPTIN
CN109111443A (en) * 2018-08-28 2019-01-01 上海迪赛诺药业股份有限公司 The novel crystal forms and preparation method thereof of DPP-IV inhibitor class antidiabetic drug
CN110305131B (en) * 2019-07-03 2021-12-31 山东百诺医药股份有限公司 Novel crystal form of linagliptin and preparation method thereof
WO2021250995A1 (en) * 2020-06-10 2021-12-16 有機合成薬品工業株式会社 Crystal morphology of 1-[(4-methyl-quinazoline-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-peperidine-1-yl)-xanthine
CN113754664B (en) * 2021-09-23 2022-08-16 山东罗欣药业集团股份有限公司 Linagliptin crystal form and preparation method thereof
CN118496229A (en) * 2024-05-13 2024-08-16 迪嘉药业集团股份有限公司 A new crystal form of linagliptin and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007128721A1 (en) * 2006-05-04 2007-11-15 Boehringer Ingelheim Internationalgmbh Polymorphs
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2007128721A1 (en) * 2006-05-04 2007-11-15 Boehringer Ingelheim Internationalgmbh Polymorphs

Also Published As

Publication number Publication date
WO2013128379A2 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
BR112014007134A2 (en) uses of a compound of formula (b), compounds, pharmaceutical composition, method of preparing the compound and use of an effective amount of a compound
WO2013128379A3 (en) Crystalline polymorphic forms of linagliptin
EP2669289A4 (en) Phosphorus substituted group-containing quinoline-like compound, its preparation process, medical composition containing the compound and application
HUP1000069A2 (en) New salts for the preparation of pharmaceutical composition
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
WO2010092090A3 (en) Novel salts of sitagliptin
WO2014072961A3 (en) Polymorphic forms of suvoroxant
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
IL232577A (en) Morpholinylbenzotriazine derivatives, their preparation and pharmaceutical compositions containing them
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
IL223872A (en) Pyrazoloquinolines and intermediate compounds, process for their preparation, use thereof and medicaments and pharmaceutical compositions comprising them
EP2924042A4 (en) Bis- -carboline compound and preparation method, pharmaceutical composition and use thereof
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
WO2012137227A3 (en) Solid forms of antiretroviral compounds and anti-oxidative acids, processes for preparation and pharmaceutical compositions thereof
IL228019A (en) Compounds as histamine h3 receptor ligands, pharmaceutical compositions, process of preparation and uses thereof
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
ZA201306905B (en) Novel octahydrothienoquinonline derivative,pharmaceutical composition comprising derivative, and use of these
IL230219B (en) Dihidropyrazole derivatives, their preparation and pharmaceutical compositions containing them
IL225105A (en) Heterocyclic compounds, process for their preparation, pharmaceutical compositions comprising them and use thereof for the preparation of medicaments
WO2011095985A3 (en) Rasagiline salts and processes for the preparation thereof
IL230907A0 (en) Salt and polymorph of pyrazolopyrimidinone compound, and pharmaceutical composition containing the same, preparation method and use thereof
CA2818993A1 (en) Modulators of s1p receptors
IL218764A (en) Crystalline levofolinic acid and process for its preparation, uses therof and pharmaceutical compositions comprising the same
WO2013153161A3 (en) Polymorph of rilpivirine hydrochloride

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13754427

Country of ref document: EP

Kind code of ref document: A2